Parasite Coverage For Pets with Taste.
The Credelio Family of Products is for pets taste, offering a consistent standard of ease, efficacy, and extra care that helps veterinarians and staff confidently navigate across the portfolio to fit the right product with the right client.
Care That Puts Pets and Personality First
Care That Puts Pets and Personality First
No two patients are the same—and neither are their tastes. The Credelio Family pairs palatable taste with proven parasite coverage for dogs and cats, helping drive compliance for clients and confidence for your clinic.
Built to deliver Ease, Efficacy, and a little bit Extra – supporting both patient needs and client expectations.
Protection That Fits Your Clinic Needs
An oral portfolio for dogs and cats, built to help you recommend with confidence.
EASE
Proven, palatable coverage. The Credelio Family’s palatability translates into real-world administration success—not just in theory, but in field studies.
*U.S. field study (567 doses, 198 dogs): 80.4% from hand or in an empty bowl, 13.6% taken with food, 6% when placed in mouth
†U.S. field study (648 doses, 225 cats): 21.1% from hand, 25.8% taken with food, 52.6% when placed in mouth, 0.5% not administered
EFFICACY
Fast-acting parasite coverage helps give you and your clients confidence
Tick Efficacy for Dogs:
Tick Efficacy for Dogs:
In two head-to-head studies in dogs, lotilaner was proven to kill multiple species of ticks (I. scapularis and A. americanum) faster‡ than sarolaner in Simparica Trio® and afoxolaner in NexGard® and NexGard® Plus.2,3
Flea Efficacy for Dogs:
In a head-to-head, well-controlled laboratory study, 100% of dogs were flea-free with lotilaner after 3 monthly doses vs. 93% with afoxolaner.4
Tick Efficacy for Cats:
Tick Efficacy for Cats:
Credelio Cat demonstrated >97% effectiveness against Ixodes scapularis ticks 72 hours after administration or infestation after 31 days.
Flea Efficacy for Cats:
In a 90-day study, Credelio Cat’s flea efficacy outperformed Frontline® Plus (fipronil), killing 99.9% of fleas at day 90 compared to 84.7% for Frontline Plus.5
‡Based on the time to statistical significance vs. control in two separate head-to-head studies. The first study compared Credelio® (lotilaner)—not Credelio Quattro™, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio® (sarolaner, moxidectin, and pyrantel) and NexGard® (afoxolaner) against Amblyomma americanum. The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel, to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis.
EXTRA
Ongoing innovation and our satisfaction guarantee mean long-term partnerships for you and pet owners
The Credelio Family is positioned for long-term partnership.
The Credelio Family is positioned for long-term partnership.
The Credelio Family of Products is backed by offerings that support your business and your clients' satisfaction, ranging from product guarantees, clinic program support, to continued label expansions.
Ongoing development against common parasites and emerging threats.
Lotilaner, the active ingredient in the Credelio Family of Products, has been shown to be an effective active ingredient to treat New World screwworm larvae when used in conjunction with proper wound care.
- Credelio and Credelio Cat were the first to receive Emergency Use Authorization for New World screwworm larvae.
- Credelio Quattro-CA1 is the first and only isoxazoline endectocide to receive conditional approval for the treatment of New World screwworm larvae infestations in dogs, pending a full demonstration of effectiveness.
Extra-Purified Lotilaner.
During the manufacturing process, an extra purification step is used to filter the inactive lotilaner enantiomer from the racemic mixture, isolating lotilaner for use in the final product.6
For Patients with a Taste for Convenient, Broad-Spectrum Coverage for Dogs
Only Credelio Quattro/Credelio Quattro-CA1 covers more types of parasites than other chewable brands of its kind§, targeting 7 parasite types^ in one chewable tablet.
§Based on label comparison of the number of parasite types covered in an isoxazoline endectocide.
^Credelio Quattro protects dogs against ticks, fleas, heartworm disease, roundworms, hookworms and tapeworms. Credelio Quattro-CA1 is conditionally approved for the treatment of New World screwworm larvae infestations in dogs pending a full demonstration of effectiveness.
For Patients Looking for Tasty* and Fast-Acting Ectocide Protection for Dogs
Don’t give ticks and fleas a fighting chance. Credelio delivers consistent tick and flea protection that lasts all month long in a small, tasty* chewable.
*U.S. field study (567 doses, 198 dogs): 80.4% from hand or in an empty bowl, 13.6% taken with food, 6% when placed in mouth.
For Finicky Felines Needing Tasty† Flea and Tick Protection
The first and only oral flea and tick protection for cats. Credelio Cat was specifically developed with feline preferences in mind. Made with a vanilla-yeast flavor and scent combination designed to support ease of administration, resulting in a 99.5% administration rate.7,†
†U.S. field study (648 doses, 225 cats): 21.1% from hand, 25.8% taken with food, 52.6% when placed in mouth, 0.5% not administered.
Efficacious Coverage + Palatability + Ongoing Development and Support = Confidence.
Efficacious Coverage + Palatability + Ongoing Development and Support = Confidence.
Contact Your Elanco Sales Rep to Learn More!
Resources
Credelio Quattro/Credelio Quattro CA-1
Indications: Credelio Quattro is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Borrelia burgdorferi infections (also known as Lyme disease) as a direct result of killing Ixodes scapularis vector ticks.
Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS; Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information: Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.
Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. Treatment of NWS myiasis includes removal of the larvae, lesion cleaning and surgical debridement. Implement appropriate wound care and pain management.
For full prescribing information, see the Credelio Quattro/Credelio Quattro-CA1 package insert.
Credelio
Emergency Use Authorization for Credelio (lotilaner) for New World screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. However, Credelio is not approved for this use.
Credelio is approved for other uses.
For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.
Limitations of Authorized Use
Credelio (lotilaner) is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indications: Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) Rhipicephalus sanguineus (brown dog tick) and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater. Credelio is indicated for the prevention of Borrelia burgdorferi infections (also known as Lyme disease) as a direct result of killing Ixodes scapularis vector ticks.
Important Safety Information: Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio package insert.
Credelio CAT
Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS)
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.
Credelio CAT is approved for other uses.
For additional information on the EUA, please refer to the Credelio CAT NWS Fact Sheet.
Limitations of Authorized Use
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Indications
Credelio® CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 lbs or greater.
Credelio® CAT is also indicated for treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older and weighing 2.0 lbs or greater.
Important Safety Information
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio® CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio® CAT against Ixodes scapularis in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, tachypnea and vomiting. For full prescribing information see the Credelio® CAT package insert.
